To see the effect of Shatavari gudam and triphaa kashyaya vaginal douch in white discharge.

Phase 2

• Conditions: Health Condition 1: N889- Noninflammatory disorder of cervixuteri, unspecifiedHealth Condition 2: N80-N98- Noninflammatory disorders of female genital tract

• Registration Number: CTRI/2021/03/031979
• Lead Sponsor: Central Council for Research in Ayurvedic Sciences New Delhi

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: ot Yet Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1 Married woman of age between 18 to 40 years.

2 Vaginal white discharge with or without associated symptoms since one month

3 Women agree to refrain from use of other douches, oral or intra-vaginal antibiotics or antifungal agents or lubricants during the entire study period.

4 Willing and ability to give written consent to participate in the study.

Exclusion Criteria

• Post-menopausal women and women undergone hysterectomy.

•Pregnant or Lactating women.

•Patients on Oral Contraceptive Pills or IUCD.

•Patients with physiological leucorrhoea (e.g. during ovulation, pre-menstrual period)

•Patients with abnormal (excessive) vaginal discharge due to neoplasmic changes, cervical intra-epithelial neoplasia or cervical carcinoma.

•Severe Anaemic (Hb% <7 gm)women.

•Immunocompromised states and patients with systemic infections or known cases of AIDS, HIV, STD etc.

•Patients with history of cardiac, hepatic, cerebrovascular disease, pulmonary dysfunction, malignancy, chronic uncontrolled systemic diseases or renal disorder ( S. Creatinine >1.2 mg/dl) etc or poorly controlled Hypertension (Blood pressure more than 160/100mm of Hg), uncontrolled Diabetes Mellitus (HbA1c >= 8), or any other serious medical illness.

•Patients on medication with corticosteroids or any other drugs that may have an influence on the outcome of the study.

•Women who have received antifungal or antimicrobial therapy (systemic or intra-vaginal) in the last one month prior to screening.

•History of hypersensitivity to the trial drug or any of its ingredients.

•Patients who have completed participation in any other clinical trial during the past 03 months.

•Any other condition which the Investigator thinks may jeopardize the study.

Study & Design

• Study Type: Interventional
• Study Design: Not specified